Association between theLRP1BandAPOEloci and the development of Parkinson’s disease dementia
Authors:
- Raquel RealRRRaquel Real
- Alejandro Martinez-CarrascoAMAlejandro Martinez-Carrasco
- Regina H ReynoldsRRRegina H Reynolds
- Michael A LawtonMLMichael A Lawton
- Manuela M X TanMTManuela M X Tan
- Maryam ShoaiMSMaryam Shoai
- Jean-Christophe CorvolJCJean-Christophe Corvol
- Mina RytenMRMina Ryten
- Catherine BresnerCBCatherine Bresner
- Leon HubbardLHLeon Hubbard
- Alexis BriceABAlexis Brice
- Suzanne LesageSLSuzanne Lesage
Open Access
- 9 November 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 146 (5) , 1873-1887
Abstract
Parkinson’s disease is one of the most common age-related neurodegenerative disorders. Although predominantly a motor disorder, cognitive impairment and dementia are important features of Parkinson’s disease, particularly in the later stages of the disease. However, the rate of cognitive decline varies among Parkinson’s disease patients, and the genetic basis for this heterogeneity is incompletely understood. To explore the genetic factors associated with rate of progression to Parkinson’s disease dementia, we performed a genome-wide survival meta-analysis of 3,923 clinically diagnosed Parkinson’s disease cases of European ancestry from four longitudinal cohorts. In total, 6.7% of individuals with Parkinson’s disease developed dementia during study follow-up, on average 4.4 ± 2.4 years from disease diagnosis. We have identified the APOE ε4 allele as a major risk factor for the conversion to Parkinson’s disease dementia [hazards ratio = 2.41 (1.94–3.00), P = 2.32 × 10−15], as well as a new locus within the ApoE and APP receptor LRP1B gene [hazards ratio = 3.23 (2.17–4.81), P = 7.07 × 10−09]. In a candidate gene analysis, GBA variants were also identified to be associated with higher risk of progression to dementia [hazards ratio = 2.02 (1.21–3.32), P = 0.007]. CSF biomarker analysis also implicated the amyloid pathway in Parkinson’s disease dementia, with significantly reduced levels of amyloid β42 (P = 0.0012) in Parkinson’s disease dementia compared to Parkinson’s disease without dementia. These results identify a new candidate gene associated with faster conversion to dementia in Parkinson's disease and suggest that amyloid-targeting therapy may have a role in preventing Parkinson’s disease dementia.Keywords
All Related Versions
Funding Information
- Aligning Science Across Parkinson's (ASAP-000478)
- Michael J. Fox Foundation
This publication has 94 references indexed in Scilit:
- APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association studyMolecular Psychiatry, 2013
- LDLR-related protein 10 (LRP10) regulates amyloid precursor protein (APP) trafficking and processing: evidence for a role in Alzheimer’s diseaseMolecular Neurodegeneration, 2012
- Trafficking and Proteolytic Processing of APPCold Spring Harbor Perspectives in Medicine, 2012
- LRAD3, A Novel Low-Density Lipoprotein Receptor Family Member That Modulates Amyloid Precursor Protein TraffickingJournal of Neuroscience, 2011
- LRP1b shows restricted expression in human tissues and binds to several extracellular ligands, including fibrinogen and apoE – carrying lipoproteinsAtherosclerosis, 2011
- Genome-wide association study of CSF biomarkers Aβ 1-42 , t-tau, and p-tau 181p in the ADNI cohortNeurology, 2011
- GCTA: A Tool for Genome-wide Complex Trait AnalysisThe American Journal of Human Genetics, 2011
- METAL: fast and efficient meta-analysis of genomewide association scansBioinformatics, 2010
- PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage AnalysesThe American Journal of Human Genetics, 2007
- α-synuclein locus duplication as a cause of familial Parkinson's diseaseThe Lancet, 2004